How we made the decision

Exceptionally, significant new evidence may mean an update of a guideline is agreed before the next scheduled check of the need for an update. The evidence might be a single piece of evidence, an accumulation of evidence or other published NICE guidance.

For details of the process and update decisions that are available, see ensuring that published guidelines are current and accurate in developing NICE guidelines: the manual.

Evidence

This surveillance report provides an overview of a cohort screening study published since the publication of NICE guideline CG164. The results of this study, alongside topic expert feedback, were considered in detail to determine if there was an impact on the recommendations within NICE guideline CG164.

Views of stakeholders

Because this was an exceptional surveillance review, we did not consult on the decision.

NICE Surveillance programme project team

Kay Nolan
Associate director

Martin Allaby
Consultant clinical adviser

Emma McFarlane
Technical adviser

Charlotte Haynes
Senior technical analyst

The NICE project team would like to thank the topic experts who participated in the surveillance process.

ISBN: 978-1-4731-3576-5


This page was last updated: 22 November 2019